Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

r survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release anticipating future clinical and business prospects for our lead drug candidate Sulonex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: the results of the Phase 3 study for Sulonex could be inconclusive or negative; even if we receive positive results from the Phase 3 study for Sulonex, we may not be able to finalize the NDA before year end for various reasons including the completion of necessary non- clinical studies; the completion of manufacturing preparations; or other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

Keryx Contact:

Lauren Fischer

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Pipeline Review, 2015 market research report that provides ... pipeline stage using data sourced from in-house databases, ... on syringes and needles market products pipeline spread ... organizations supported with 73 tables and 5 figures ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 53D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4
... , , , , , , , , , ... and LAUSANNE, Switzerland , February 4 ... Debiopharm Group (Debiopharm), a Swiss-based global,biopharmaceutical group of companies with ... medical needs, announce the launch by,Ipsen in France ...
... , REDWOOD CITY, Calif. , Feb. ... financial results for the year ended December 31, 2009 , which ... cash flow positive. , Total revenue for the fourth quarter of 2009 ... in the fourth quarter of 2008.  Product revenue from the Onco type ...
Cached Medicine Technology:Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 2Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 3Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 4Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 5Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer 6Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
(Date:7/31/2015)... ... 31, 2015 , ... There’s no better way to enjoy the summer weather ... cook the next meal, making July the most appropriate to be National Hot Dog ... recipes. , Make the next cookout different than the ones in the past. Celebrate ...
(Date:7/31/2015)... ... ... Coco Libre announced today that their flagship Organic Coconut Water will be ... Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco Libre, ... is a natural choice given the Open’s commitment to sustainable practices. , Designated ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According to the article ... floor of the Pasadena courthouse was contained and extinguished by the city’s fire department before ... in the building at the time of the fire, and it was a fire alarm ...
(Date:7/31/2015)... , ... July 31, 2015 ... ... T. Brown’s live lecture on pharmaceutical negligence is now available online at ... well received with a 94% approval rating from the nationwide audience. ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York Regional ... members, medical professionals, and researchers, covering a variety of topics related to mesothelioma ... effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer Center. ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
... is the centerpiece of the U.S. Agency for International,Development,s ... plagued by community unrest., The Haiti Basic Education ... and private primary schools as well as youths no ... worldwide education and,health program for USAID., "In Haiti, ...
... Benjamin, MD, FACP, FACEP (E), Executive,Director, American Public ... American Public,Health Association strongly urges U.S. House members ... give the Food and Drug Administration (FDA),the authority ... is responsible for more than 400,000 deaths each,year ...
... in blood and spinal fluid seem likely candidates, researchers say ... succeeding in the hunt for biomarkers for Alzheimer,s disease. , ... gives an indication of what,s going on inside the body ... and, once doctors have better drugs for Alzheimer,s, with earlier ...
... YORK, July 29 Dr. Jamie Sands, DDS, of ... a lot about who you are,it shouldn,t say anything ... Oral-B Vitality powered toothbrush and Crest Glide Floss,can help ... Crest at:, http://media.medialink.com/WebNR.aspx?story=35391 ), Registered journalists can ...
... WASHINGTON, July 29 A coalition of consumer,advocacy and ... Patent Office (USPTO) rules that would curtail abusive behavior ... used,frequently by drug companies to get patents they don,t ... District Court of Appeals,for the Federal Circuit in Washington, ...
... Medical Center of Santa Rosa, SANTA ROSA, Calif., ... United Healthcare Workers - West:, Healthcare workers will ... alarm at a growing healthcare crisis in Sonoma,County that ... next,month. The announced elimination of 120 SMCSR workers would ...
Cached Medicine News:Health News:Three Rs and HIV/AIDS Mark New Haiti Literacy Plan 2Health News:'Biomarkers' May Help Spot, Track Alzheimer's 2Health News:Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants 2Health News:Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants 3Health News:Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants 4Health News:Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants 5Health News:Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants 6Health News:Public Interest Groups Back Federal Court Appeal to Implement New U.S. Patent Rules; Proposed Regulations Would Curtail Abusive Behavior by Patent Applicants 7Health News:Workers Denounce Sutter Health's Disregard for Community Interests 2
For the qualitative determination of magnesium in serum....
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Medicine Products: